• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Pliant Therapeutics Inc (NQ: PLRX )

    10.86 +0.34 (+3.23%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,151,523
    Open 11.01
    Bid (Size) 10.35 (1)
    Ask (Size) 12.52 (1)
    Prev. Close 10.52
    Today's Range 10.54 - 11.40
    52wk Range 10.29 - 20.23
    Shares Outstanding 35,937,937
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    7 Biotech Stocks to Buy on the Dip: June 2024
    With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation. 
    Via InvestorPlace
    Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -39.53%
    -39.53%
    1 Month
    -5.65%
    -5.65%
    3 Month
    -26.22%
    -26.22%
    6 Month
    -44.56%
    -44.56%
    1 Year
    -42.23%
    -42.23%

    More News

    Read More
    Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    These Analysts Revise Their Forecasts On Pliant Therapeutics Following Q1 Earnings
    Via Benzinga
    The Latest Analyst Ratings for Pliant Therapeutics
    Via Benzinga
    Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    Pliant Therapeutics' Drug Trial Shows Promise In Reversing Lung Fibrosis In Patients
    Via Benzinga
    Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    PLRX Stock Earnings: Pliant Therapeutics Misses EPS for Q1 2024
    Via InvestorPlace
    Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    Pliant Therapeutics to Participate in Upcoming Investor Events
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    Pliant Therapeutics to Participate in Upcoming Investor Events
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    Pliant Therapeutics to Participate in Upcoming Investor Conferences
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    Pliant Therapeutics to Participate in Upcoming Investor Events
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Why Is Liver Disease-Focused Pliant Therapeutics Stock Trading Lower Today?
    Via Benzinga
    HC Wainwright & Co. Maintains Buy Rating for Pliant Therapeutics: Here's What You Need To Know
    Via Benzinga
    Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.